A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISEHeather Payne, Maria De Santis, Roberto Bordonaro et al.|International Journal of Cancer|2021Cited by 19
A European prospective observational study of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC): PREMISEHeather Payne, Marco De Santis, Angus Robinson et al.|European Urology Open Science|2020Cited by 1
Pain outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving enzalutamide (ENZA) in a real-world setting: PREMISEDavid Mott, Marco Pavesi, Michael Herdman et al.|European Urology Open Science|2020Cited by 0